These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 10677750)

  • 21. An update on benznidazole for the treatment of patients with Chagas disease.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of congenital Chagas through treatment of girls and women of childbearing age.
    Moscatelli G; Moroni S; García-Bournissen F; Ballering G; Bisio M; Freilij H; Altcheh J
    Mem Inst Oswaldo Cruz; 2015 Jun; 110(4):507-9. PubMed ID: 25993401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Evaluation of complement mediated lysis technic in patients with chronic Chagas' disease treated with trypanocidal drugs].
    Levy AM; Pereira VL; Boainain E
    Rev Inst Med Trop Sao Paulo; 1988; 30(1):32-9. PubMed ID: 3146793
    [No Abstract]   [Full Text] [Related]  

  • 24. Reversibility of muscle and heart lesions in chronic, Trypanosoma cruzi infected mice after late trypanomicidal treatment.
    Segura MA; Molina de Raspi E; Basombrio MA
    Mem Inst Oswaldo Cruz; 1994; 89(2):213-6. PubMed ID: 7885247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission.
    Sosa-Estani S; Cura E; Velazquez E; Yampotis C; Segura EL
    Rev Soc Bras Med Trop; 2009; 42(5):484-7. PubMed ID: 19967227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ideal benznidazole dose regimen in chronic chagasic patients: a systematic review.
    Rev Inst Med Trop Sao Paulo; 2020; 62():e52err. PubMed ID: 32844906
    [No Abstract]   [Full Text] [Related]  

  • 27. Chronic Chagas disease with advanced cardiac complications in Japan: Case report and literature review.
    Imai K; Maeda T; Sayama Y; Osa M; Mikita K; Kurane I; Miyahira Y; Kawana A; Miura S
    Parasitol Int; 2015 Oct; 64(5):240-2. PubMed ID: 25744336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chagasic meningoencephalitis with detection of Trypanosoma cruzi in the cerebrospinal fluid of an immunodepressed patient.
    Jardim E; Takayanagui OM
    J Trop Med Hyg; 1994 Dec; 97(6):367-70. PubMed ID: 7966540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meningoencephalitis in a patient with acute Chagas disease in the Brazilian Amazon.
    Medeiros MB; Guerra JA; Lacerda MV
    Rev Soc Bras Med Trop; 2008; 41(5):520-1. PubMed ID: 19009201
    [No Abstract]   [Full Text] [Related]  

  • 30. Congenital Chagas disease reported in United States.
    Voelker R
    JAMA; 2012 Aug; 308(5):443. PubMed ID: 22851094
    [No Abstract]   [Full Text] [Related]  

  • 31. Antitrypanosomal therapy for chronic Chagas' disease.
    Bern C
    N Engl J Med; 2011 Jun; 364(26):2527-34. PubMed ID: 21714649
    [No Abstract]   [Full Text] [Related]  

  • 32. Nanomedicines against Chagas disease: an update on therapeutics, prophylaxis and diagnosis.
    Morilla MJ; Romero EL
    Nanomedicine (Lond); 2015 Feb; 10(3):465-81. PubMed ID: 25707979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial.
    Viotti R; Vigliano C; Lococo B; Bertocchi G; Petti M; Alvarez MG; Postan M; Armenti A
    Ann Intern Med; 2006 May; 144(10):724-34. PubMed ID: 16702588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Experimental study on the therapeutic action of Ro 7-1051 on infections caused by different strains of Trypanosoma cruzi].
    Andrade SG; Figueira RM
    Rev Inst Med Trop Sao Paulo; 1977; 19(5):335-41. PubMed ID: 416483
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease.
    Corrales M; Cardozo R; Segura MA; Urbina JA; Basombrío MA
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1556-60. PubMed ID: 15793138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levels of anti-B13 antibodies over time in a cohort of chronic infected by Trypanosoma cruzi. Its relationship with specific treatment and clinical status.
    Olivera V; Bizai ML; Arias E; Suasnabar S; Bottasso O; Marcipar I; Fabbro D
    Acta Trop; 2021 Jun; 218():105908. PubMed ID: 33789152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of Trypanosoma cruzi purified glycoprotein (GP57/51) or trypomastigote-shed antigens to assess cure for human Chagas' disease.
    Gazzinelli RT; Galvao LM; Krautz G; Lima PC; Cancado JR; Scharfstein J; Krettli AU
    Am J Trop Med Hyg; 1993 Nov; 49(5):625-35. PubMed ID: 8250103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
    Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts.
    Guedes PM; Urbina JA; de Lana M; Afonso LC; Veloso VM; Tafuri WL; Machado-Coelho GL; Chiari E; Bahia MT
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4286-92. PubMed ID: 15504854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trypanosoma cruzi: Immunological predictors of benznidazole efficacy during experimental infection.
    Fernández MC; González Cappa SM; Solana ME
    Exp Parasitol; 2010 Feb; 124(2):172-80. PubMed ID: 19747482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.